1Gokbuget N,Hoelzer D.Treatment of adult acute lymphoblastic leukemia[J].Semin Hematol,2009,46(1):64-75.
2Ottmann OG,Pfeifer H.First-line treatment of philadelphia chromosome-positive acute lymphoblastic leukemia in adults[J].Curr Opin Oncol,2009,21(1):43-46.
3Thomas DA,Kantarjian HM,Cortes J,et al.Outcome after frontline therapy with the hyper-CVAD and imatinib mesylate regimen for adults with de novo or positive acute lymphoblastic leukemia(ALL)[J].Blood,2008,112:1008.
4Chalandon Y,Thomas X,Hayette S,et al.First results of the GRAAPH-2005 study in younger adult patients with de novo Philadelphia positive acute lymphoblastic leukemia[J].Blood,2008,112:11.
5Ravandi F,Thomas DA,Kantarjian HM,et al.Phase II study of combination of hyperCVAD with dasatinib in frontline therapy of patients with Philadelphia chromosome(Ph) positive acute lymphoblastic leukemia (ALL)[J].Blood,2008,112:1005.
6Foa R,Vitale A,Guarini A,et al.Line treatment of adult Ph+ acute lymphoblastic leukemia patients.Final results of the GIMEMALAL1205 study[J].Blood,2008,112:305.
7Jones D,Thomas D,Yin CC,et al.Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors[J].Cancer,2008,113(5):985-994.
8Pfeifer H,Wystub S,Wassmann B,et al.Minimal residual disease and mutational status prior to and after SCT for patients with philadelphia-chromosome-positive acute lymphoblastic leukemia(Ph+ ALL)[J].Blood,2008,112:261.
9Porkka K,Koskenvesa P,Lundan T,et al.Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia[J].Blood,2008,112(4):1005-1012.
10Fielding AK,Rowe JM,Richards SM,et al.Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneit transplantation over chemotherapy in the pre-imatinib era:results from the International ALL Trial MRC UKALLXII/ECOG2993[J].Blood,2009,113(19):4489-4496.
